https://www.selleckchem.com/pr....oducts/brm-brg1-atp-
7% (95% CI 45.4-56.1) with bevacizumab. The rate difference (- 4.2%; 90% CI - 10.6 to 2.1) and rate ratio (0.92; 90% CI 0.80-1.05) both fell within the prespecified equivalence margins. No notable differences were observed between treatment groups in any efficacy endpoints or their subgroup analyses. Safety, immunogenicity, and pharmacokinetic profiles were comparable between the two treatment groups. HLX04 demonstrated equivalent efficacy with similar safety and immunogenicity profiles to reference bevacizumab among pa
Aimer
Commentaire
Partagez
